2019年冠状病毒病（COVID-19）相关的毛霉菌病在印度次大陆呈上升趋势。我们报告了一例新诊断的年轻糖尿病患者皮肤毛霉菌病的独特病例，该患者患有严重的COVID-19肺炎并伴有COVID后肺纤维化。他之前也没有任何外伤或伤口，也没有任何二次传播的证据。没有任何证据的皮肤毛霉菌病是闻所未闻的。在这种情况下，可能的危险因素是使用高级抗生素的多种细菌继发感染，使用伏立康唑治疗可能的曲霉病，和类固醇的使用。
■TambeRR，印度教A,SunilS,VaraiyaA,严重COVID-19肺炎患者的皮肤毛霉菌病：比罕见病例报告更罕见。印度JCritCareMed2021；25（11）：1318-1319。
Coronavirus disease-2019 (COVID-19)-associated mucormycosis is on the rise in the Indian subcontinent. We report a unique
case of cutaneous mucormycosis in a
case of newly diagnosed young diabetic patient with severe COVID-19 pneumonia with post-COVID lung fibrosis. Neither did he have any preceding trauma or wound, nor was there any evidence of any secondary dissemination. Cutaneous mucormycosis without evidence of either is unheard off. Possible risk factors in this
case were multiple bacterial secondary infections with the use of higher antibiotics, use of voriconazole for possible aspergillosis, and steroid use.
UNASSIGNED: Tambe RR, Hinduja A, Sunil S, Varaiya A, Joshi A. Cutaneous Mucormycosis in a Patient of Severe COVID-19 Pneumonia: A Rarer than Rare
Case Report. Indian J Crit Care Med 2021;25(11):1318-1319.
PDF(Pubmed)